NICM
IDXX icon

Neo Ivy Capital Management’s Idexx Laboratories IDXX Stock Holding History

Neo Ivy Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-566
Closed -$277K – 521
2021
Q1 		$277K Buy
+566
New +$284K 0.3% 116
2019
Q1 		– Sell
-2,062
Closed -$384K – 334
2018
Q4 		$384K Buy
+2,062
New +$423K 0.3% 148

Other funds holding IDXX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Neo Ivy Capital Management's IDXX Position: Q2 2021 in Review

Neo Ivy Capital Management sold out of Idexx Laboratories (IDXX) in Q2 2021, closing a stake of 566 shares — an estimated $277K sold.

Neo Ivy Capital Management first reported a position in IDXX in Q4 2018 and held it in 2 quarters. The position peaked at $384K in Q4 2018. 1,034 funds tracked by Wall St. Rank hold IDXX as of Q2 2021.

  • Neo Ivy Capital Management reported no remaining Idexx Laboratories position as of Q2 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 566 Idexx Laboratories shares in Q2 2021, an estimated $277K.
  • Neo Ivy Capital Management first reported a position in Idexx Laboratories in Q4 2018 and held it in 2 quarters.
  • Neo Ivy Capital Management's Idexx Laboratories position peaked at $384K in Q4 2018.
  • 1,034 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2021.

Based on Neo Ivy Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.